Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).
Tom van den EndeNicolien C de ClercqMark Ivo van Berge HenegouwenSuzanne Sarah GisbertzE D GeijsenR H A VerhoevenSybren L MeijerSandor SchokkerM P G DingsJacques J G H M BergmanNadia Haj MohammadJelle P RuurdaRichard van HillegersbergStella MookMax NieuwdorpTanja D de GruijlTanya T D SoeratramBauke YlstraNicole C T van GriekenMaarten F BijlsmaMaarten C C M HulshofH W M van LaarhovenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Combining nCRT with atezolizumab is feasible in patients with rEAC. On the basis of our exploratory biomarker study, future studies are necessary to elucidate the potential of neoadjuvant immunotherapy in patient subgroups.See related commentary by Catenacci, p. 3269.